Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buntanetap in Early Alzheimer's Disease
NCT06709014Phase 3Active, not recruiting
- Sponsor
- Annovis Bio, Inc.
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buntanetap in Alzheimer's disease (AD), sponsored by Annovis Bio, Inc.. Started Feb 2025; status: active, not recruiting.
02
Drugs
buntanetap
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06709014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709014.